IRLAB Therapeutics AB
STO:IRLAB A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IRLAB Therapeutics AB
STO:IRLAB A
|
SE |
|
AVT Natural Products Ltd
NSE:AVTNPL
|
IN |
|
Goodfood Market Corp
TSX:FOOD
|
CA |
|
T
|
TATA Health International Holdings Ltd
HKEX:1255
|
HK |
|
Gree Electric Appliances Inc of Zhuhai
SZSE:000651
|
CN |
|
Mayfield Group Holdings Ltd
ASX:MYG
|
AU |
|
EnPro Industries Inc
NYSE:NPO
|
US |
|
S
|
Space Hellas SA
XBER:H9LA
|
GR |
|
L
|
Localiza Rent a Car SA
BOVESPA:RENT3
|
BR |
|
Inner Mongolia Dian Tou Energy Corp Ltd
SZSE:002128
|
CN |
IRLAB Therapeutics AB
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
IRLAB Therapeutics AB engages in the provision of novel treatments for disorders of the brain that focuses on illness in the central nervous system. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-02-28. The company focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinson’s disease. The firm possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The firm operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinson’s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
